PROMIS-AD Study

Purpose

In this clinical trial, we are testing the effectiveness of repetitive Transcranial Magnetic Stimulation (TMS) on the treatment of Alzheimer’s Disease. We welcome English-speaking individuals age 55 to 100 years old with an Alzheimer’s Disease diagnosis to enroll. Participants will receive either active or sham TMS, and those who receive sham stimulation may be eligible to receive open-label active treatment after the completion of the study. Participation in the study would last up to 9 weeks for those receiving active stimulation and up to 18 weeks for those receiving sham.

(PI: Michael Leuchter, MD)

Contact: Griffin Bohman or Ellie Pinkerton at tmsresearch@mednet.ucla.edu or call (310) 825-4781 to participate or for more information.

IRB Protocol IRB#20-1417

More information on the PROMIS-AD study is available at clinicaltrials.gov ID#: NCT06597942.